Biogen Profit Margin

The latest profit margin for BIIB is 8.33% as of June 2026. That compares with 15.31% in the prior-year period — down 45.6% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Biogen's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIIB's profit margin moved from 15.31% to 8.33% — a 45.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biogen's valuation or profitability profile.

Against Healthcare companies, BIIB currently prints 8.33% for profit margin, while the sector average sits near 14.41%. That is roughly 42.2% below the sector mean. Large gaps often invite a closer look at Biogen's growth, margins, and balance sheet.

Profit Margin shows how effectively Biogen converts resources into returns. At 8.33%, BIIB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 15.31% in the prior-year period — down 45.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BIIB's profit margin (8.33%), review year-over-year change from 15.31%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.